Novo Nordisk Makes Case For Alogliptin-Shadowed Victoza
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo hopes the differing drug class and bigger Phase III trial will help diabetes drug get past heart-safety rules that tripped up the compound from Takeda.